The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new targeted drug for the inflammatory skin disease in over a decade ...

Antihistamines are often tried, but they usually only work half the time. Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade.

Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a three-part, phase 3 trial in which ...

The monoclonal antibody dupilumab has been approved for the treatment of adults and adolescents with asthma as well as with other type 2 inflammatory diseases. In this 52-week phase 3, randomized ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more ...

Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's efficacy in children with atopic dermatitis and co ...

The Heads Up study evaluated upadacitinib (30 mg, once daily) versus dupilumab (300 mg, every other week) in adults with moderate to severe atopic dermatitis[1] - The safety profile of ...

Children with concomitant atopic dermatitis (AD) and alopecia areata (AA) who were treated with dupilumab demonstrated significant hair regrowth over a mean of nearly 68 weeks, preliminary results ...

Researchers compared dupilumab use with other and with no systemic therapy. Dupilumab inhibits IL-4 and IL-13, which have been linked to internal tumorigenesis. Perspective from Raj Chovatiya ...